#NeoALTTO - Twitter Hashtag

over 3 years ago

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the #OvarianReserve of Young Women With HER2-Positive #BreastCancer: https://t.co/dB2GDrK4zd #hsronc by @matteolambe @E_de_Azambuja @IDemeestere et al #BCSM #fertility #oncofertility #NeoALTTO #HER2

JNCCN's tweet photo. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the #OvarianReserve of Young Women With HER2-Positive #BreastCancer: https://t.co/dB2GDrK4zd
#hsronc by @matteolambe @E_de_Azambuja @IDemeestere et al
#BCSM #fertility #oncofertility #NeoALTTO #HER2 https://t.co/d5N9r3HCgu

0

11

4

1

2K

Luca Arecco, MD @Lucarecco

over 3 years ago

🗞️This is a biomarker analysis of the randomized phase III neoadjuvant #NeoALTTO trial. In this analysis, 130 premenopausal women <45 years (median age: 38 years) with diagnosis of HER2+ early breast cancer with available serum samples were included.

Lucarecco's tweet photo. 🗞️This is a biomarker analysis of the randomized phase III neoadjuvant #NeoALTTO trial.

In this analysis, 130 premenopausal women <45 years (median age: 38 years) with diagnosis of HER2+ early breast cancer with available serum samples were included. https://t.co/zhNFJqd2KT

1

3

2

0

532

Matteo Lambertini, MD PhD @matteolambe

over 3 years ago

Important start of 2023 with our #NeoALTTO gonadotoxicity analysis: weekly paclitaxel + #trastuzumab should not be considered completely gonadal safe...proper #oncofertility counseling is mandatory also in these women @OncoAlert #bcsm #BreastCancer #HER2 https://t.co/wRKskxb5n1

matteolambe's tweet photo. Important start of 2023 with our #NeoALTTO gonadotoxicity analysis: weekly paclitaxel + #trastuzumab should not be considered completely gonadal safe...proper #oncofertility counseling is mandatory also in these women

@OncoAlert #bcsm #BreastCancer #HER2

https://t.co/wRKskxb5n1 https://t.co/ecvu1x9gii

2

102

30

9

17K

Matteo Lambertini, MD PhD @matteolambe

over 4 years ago

Now at #ASCO22 our @BIGagainstBC @_SOLTI #NeoALTTO analysis showing the gonadotoxicity of anti-#HER2 therapy plus #paclitaxel in premenopausal women with #BreastCancer @AnnPartridgeMD @E_de_Azambuja @Lucarecco @CristinaSaura3 @AIRC_it @UniGenova @SanMartino_Ge #UNIGEnonsiferma

matteolambe's tweet photo. Now at #ASCO22 our @BIGagainstBC @_SOLTI #NeoALTTO analysis showing the gonadotoxicity of anti-#HER2 therapy plus #paclitaxel in premenopausal women with #BreastCancer

@AnnPartridgeMD @E_de_Azambuja @Lucarecco @CristinaSaura3
@AIRC_it @UniGenova @SanMartino_Ge #UNIGEnonsiferma https://t.co/i4I0WmgYo7

0

22

9

0

Matteo Lambertini, MD PhD @matteolambe

almost 8 years ago · Steenokkerzeel

Published in @JournalCancer our @BIGagainstBC #ALTTO #NeoALTTO analysis of safety and outcomes of #pregnancies during and after #trastuzumab and/or #lapatinib in #HER2+ #BreatCancer patients: can’t wait to hear Dr. Linn talk at #ESMO18 on this topic #bcsm https://t.co/xUugT6O98C

matteolambe's tweet photo. Published in @JournalCancer our @BIGagainstBC #ALTTO #NeoALTTO analysis of safety and outcomes of #pregnancies during and after #trastuzumab and/or #lapatinib in #HER2+ #BreatCancer patients: can’t wait to hear Dr. Linn talk at #ESMO18 on this topic #bcsm
https://t.co/xUugT6O98C https://t.co/CWH9NgrD6D

3

17

13

1

0

Matteo Lambertini, MD PhD @matteolambe

about 8 years ago · Sint-Gillis

Great opportunity also for #YoungOncologists to apply with research projects within the @BIGagainstBC #NeoALTTO and #ALTTO trials in the setting of #HER2-positive early #BreastCancer #bcsm #ResearchSavesLives #CancerResearch

0

9

4

0

Matteo Lambertini, MD PhD @matteolambe

over 8 years ago · Elsene

Proud to be in this list, can’t wait to attend #ASCO18 ! A special thank to @BIGagainstBC for featuring our study on #pregnancies during or following #Trastuzumab and/or #Lapatinib in #HER2-positive #BreastCancer patients enrolled in the #NeoALTTO and #ALTTO trials https://t.co/6X247j3kTC

0

15

7

0